JP7419273B2 - 組換えタンパク質を製造する方法 - Google Patents

組換えタンパク質を製造する方法 Download PDF

Info

Publication number
JP7419273B2
JP7419273B2 JP2020573229A JP2020573229A JP7419273B2 JP 7419273 B2 JP7419273 B2 JP 7419273B2 JP 2020573229 A JP2020573229 A JP 2020573229A JP 2020573229 A JP2020573229 A JP 2020573229A JP 7419273 B2 JP7419273 B2 JP 7419273B2
Authority
JP
Japan
Prior art keywords
cells
batch
cell
culture
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020573229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529527A5 (https=
JP2021529527A (ja
Inventor
ジャンリン・シュー
アンドリュー・ヨンキー
ティエン・ジュン
マイケル・シー・ボリス
ジェンジアン・リ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67470657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7419273(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2021529527A publication Critical patent/JP2021529527A/ja
Publication of JP2021529527A5 publication Critical patent/JP2021529527A5/ja
Priority to JP2024001657A priority Critical patent/JP2024050590A/ja
Application granted granted Critical
Publication of JP7419273B2 publication Critical patent/JP7419273B2/ja
Priority to JP2025247705A priority patent/JP2026048825A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2020573229A 2018-07-03 2019-07-02 組換えタンパク質を製造する方法 Active JP7419273B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024001657A JP2024050590A (ja) 2018-07-03 2024-01-10 組換えタンパク質を製造する方法
JP2025247705A JP2026048825A (ja) 2018-07-03 2025-12-12 組換えタンパク質を製造する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862693606P 2018-07-03 2018-07-03
US62/693,606 2018-07-03
PCT/US2019/040298 WO2020010080A1 (en) 2018-07-03 2019-07-02 Methods of producing recombinant proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024001657A Division JP2024050590A (ja) 2018-07-03 2024-01-10 組換えタンパク質を製造する方法

Publications (3)

Publication Number Publication Date
JP2021529527A JP2021529527A (ja) 2021-11-04
JP2021529527A5 JP2021529527A5 (https=) 2022-07-08
JP7419273B2 true JP7419273B2 (ja) 2024-01-22

Family

ID=67470657

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020573229A Active JP7419273B2 (ja) 2018-07-03 2019-07-02 組換えタンパク質を製造する方法
JP2024001657A Pending JP2024050590A (ja) 2018-07-03 2024-01-10 組換えタンパク質を製造する方法
JP2025247705A Pending JP2026048825A (ja) 2018-07-03 2025-12-12 組換えタンパク質を製造する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024001657A Pending JP2024050590A (ja) 2018-07-03 2024-01-10 組換えタンパク質を製造する方法
JP2025247705A Pending JP2026048825A (ja) 2018-07-03 2025-12-12 組換えタンパク質を製造する方法

Country Status (23)

Country Link
US (2) US20210253996A1 (https=)
EP (2) EP3818078B1 (https=)
JP (3) JP7419273B2 (https=)
KR (2) KR20250153311A (https=)
CN (1) CN112839954A (https=)
AU (1) AU2019299358B2 (https=)
CA (1) CA3104684A1 (https=)
DK (1) DK3818078T3 (https=)
EA (1) EA202092904A1 (https=)
ES (1) ES2976708T3 (https=)
FI (1) FI3818078T3 (https=)
HR (1) HRP20240584T1 (https=)
HU (1) HUE066560T2 (https=)
IL (2) IL324666A (https=)
LT (1) LT3818078T (https=)
MX (1) MX2020013633A (https=)
PL (1) PL3818078T3 (https=)
PT (1) PT3818078T (https=)
RS (1) RS65472B1 (https=)
SG (1) SG11202012582QA (https=)
SI (1) SI3818078T1 (https=)
SM (1) SMT202400173T1 (https=)
WO (1) WO2020010080A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK181991B1 (en) * 2021-11-11 2025-05-15 Dsm Ip Assets Bv Combined fermentation process for producing one or more human milk oligosaccharide(s) (hmo(s)) in escherichia coli
WO2023242238A1 (en) * 2022-06-15 2023-12-21 UCB Biopharma SRL Cell culture processes
EP4339274B1 (en) 2022-09-13 2025-03-26 Sartorius Stedim Biotech GmbH Method for operating a bioprocess installation for production of a bioproduct
KR20240172522A (ko) * 2023-06-01 2024-12-10 (주)알테오젠 지속형 호르몬 수용체 길항제의 생산 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015133980A (ja) 2004-08-27 2015-07-27 ファイザー・アイルランド・ファーマシューティカルズ 抗アミロイドベータ抗体の製法
JP2016000030A (ja) 2006-09-13 2016-01-07 アッヴィ・インコーポレイテッド 細胞培養の改善
JP2018076286A (ja) 2011-02-07 2018-05-17 セレニス セラピューティクス ホールディング エスアー リポタンパク質複合体ならびにその製造および使用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE68919361T2 (de) 1988-06-21 1995-05-24 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2193136T3 (es) 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2108566T3 (es) 1993-12-10 1997-12-16 Genentech Inc Procedimientos para diagnosticar alergias y para seleccionar agentes terapeuticos antialergicos.
WO1995019181A1 (en) 1994-01-18 1995-07-20 Genentech, Inc. A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
CA2242414C (en) 1996-01-23 2012-01-03 Genentech, Inc. Anti-cd18 antibodies for use against stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0941344B1 (en) 1996-11-27 2004-05-19 Genentech, Inc. HUMANIZED ANTI-CD11a ANTIBODIES
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
ES2309012T3 (es) 1999-10-29 2008-12-16 Genentech, Inc. Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
PT2837680T (pt) * 2011-07-01 2020-04-17 Amgen Inc Cultura celular de mamífero
WO2015095809A1 (en) * 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
MA40021A (fr) * 2014-06-03 2015-12-10 Lupin Ltd Processus de culture cellulaire destiné à produire une protéine
AU2015269365A1 (en) * 2014-06-04 2016-12-15 Amgen Inc. Methods for harvesting mammalian cell cultures
US9813410B2 (en) 2014-06-26 2017-11-07 Rakuten, Inc. Information processing apparatus, information processing method, and information processing program

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015133980A (ja) 2004-08-27 2015-07-27 ファイザー・アイルランド・ファーマシューティカルズ 抗アミロイドベータ抗体の製法
JP2016000030A (ja) 2006-09-13 2016-01-07 アッヴィ・インコーポレイテッド 細胞培養の改善
JP2018076286A (ja) 2011-02-07 2018-05-17 セレニス セラピューティクス ホールディング エスアー リポタンパク質複合体ならびにその製造および使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Biotechnol. Bioeng.，2012年，vol.110, no.1，p.191-205
Biotechnol. Prog.，2013年，vol.29, no.1，p.222-229
Biotechnol. Prog.，2017年01月28日，vol.33, no.4，p.867-878

Also Published As

Publication number Publication date
US20210253996A1 (en) 2021-08-19
AU2019299358B2 (en) 2026-04-02
IL324666A (en) 2026-01-01
CA3104684A1 (en) 2020-01-09
IL279782A (en) 2021-03-01
CN112839954A (zh) 2021-05-25
WO2020010080A1 (en) 2020-01-09
PL3818078T3 (pl) 2024-04-29
EP4368699A2 (en) 2024-05-15
BR112020025623A2 (pt) 2021-03-23
IL279782B1 (en) 2026-01-01
SMT202400173T1 (it) 2024-07-09
JP2024050590A (ja) 2024-04-10
PT3818078T (pt) 2024-04-18
ES2976708T3 (es) 2024-08-07
EP3818078A1 (en) 2021-05-12
AU2019299358A1 (en) 2021-02-18
EP3818078B1 (en) 2024-02-28
FI3818078T3 (fi) 2024-05-14
DK3818078T3 (da) 2024-05-21
MX2020013633A (es) 2021-03-25
US20250171732A1 (en) 2025-05-29
JP2021529527A (ja) 2021-11-04
EP4368699A3 (en) 2024-09-11
KR20250153311A (ko) 2025-10-24
SI3818078T1 (sl) 2024-05-31
KR20210027427A (ko) 2021-03-10
HRP20240584T1 (hr) 2024-07-19
KR102870511B1 (ko) 2025-10-15
SG11202012582QA (en) 2021-01-28
LT3818078T (lt) 2024-04-25
RS65472B1 (sr) 2024-05-31
JP2026048825A (ja) 2026-03-17
HUE066560T2 (hu) 2024-08-28
EA202092904A1 (ru) 2021-04-22

Similar Documents

Publication Publication Date Title
US20250171732A1 (en) Methods of producing recombinant proteins
US20220315887A1 (en) Methods of improving protein productivity in fed-batch cell cultures
US11242510B2 (en) Mammalian cells devoid of lactate dehydrogenase activity
US20090142805A1 (en) High expression cell line that eliminates gene amplification
US12486525B2 (en) Methods for increasing productivity of therapeutic proteins
EA048403B1 (ru) Способы получения рекомбинантных белков
US20250115666A1 (en) Cell culture methods for producing therapeutic proteins
BR112020025623B1 (pt) Método para a produção, em grande escala, de um polipeptídeo recombinante de interesse
CN115916814A (zh) 细胞培养方法
HK40002355A (en) Methods of decreasing trisulfide bonds during recombinant production of polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220630

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231027

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240110

R150 Certificate of patent or registration of utility model

Ref document number: 7419273

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150